the growth of tumor. 5, 6 At present, adjuvant therapy has become a major trend in clinical treatment of NSCLC, and self-made sichongsan (scorpio, centipede, earthworm, and stiff silkworm) is a kind of medication in traditional Chinese medicine. Sichongsan has been proved to be effective to the NSCLC, but the possible mechanism is unclear. This study was to investigate the efficacy of selfmade sichongsan in combination with gefitinib on NSCLC patients with EGFR mutation.
Materials and methods

General materials
We selected a total of 47 NSCLC patients in advanced stage with EGFR mutation admitted to our hospital for treatment between July 2011 and September 2016 as the subjects. Inclusion criteria include patients in stages IIIB-IV; patients aged between 21 and 79 years old; patients with EGFR mutation; patients whose lesion could be evaluated by Response Evaluation Criteria in Solid Tumors (RECIST); patients with normal results in examination of relevant indicators, including liver function, kidney function, electrocardiogram (ECG), and blood routine examination; and patients with 0 to 2 points in Eastern Cooperative Oncology Group (ECOG) scale. Exclusion criteria include patients with high intolerance or adverse effects of Grade 3 or 4, patients who could not fulfill the treatment, patients with tumor progression during treatment, and patients who required to exit. Among 47 patients, there were 22 males and 18 females, and these patients aged between 21 and 79 years old with an average of 59.7 ± 2.4 years old; as for ECOG scale, there were 32 patients with 0 or 1 point, and 15 with 1 or 2 points. These patients were divided randomly into two groups, that is, control group (n = 23) and experiment group (n = 24), and the comparison of general materials between the two groups showed no statistical significance (P > 0.05), suggesting that the general materials were comparable. This study was approved by the hospital ethics committee and received the consent of the patients and their families.
Methods
Patients in the control group underwent oral administration of gefitinib (q.d., 250 mg).
Patients in the experiment group took gefitinib in combination with self-made sichongsan (scorpio: 15 g, centipede: 15 g, earthworm: 15 g, and stiff silkworm: 15 g) in the presence or absence of peach seed (10 g), Thunberg Fritillary Bulb (10 g), semen coicis (10 g), and asparagus fern (10 g) and decocted with water (one dose per day and taken morning and night).
The treatment lasted for 12 weeks in both groups, and the complications as well as the corresponding treatment were recorded in the merged medication table.
Observation indexes
1. At the 12th week after treatment, RECIST 1.1 was used to evaluate the efficacy on patients with four degrees: CR, PR, SD, and PD. Objective response rate of treatment was calculated by dividing the number of whole patients per group to the number that patient achieved degrees CR and PR. 2. Before and at the 12th week after treatment, 3 mL peripheral blood sample was collected from the patients in both groups for centrifugation to detect the levels of carcinoembryonic antigen (CEA) and carbohydrate antigen 153 (CA153). 3. Adverse reactions of patients in both groups during the treatment.
Statistical processing SPSS 21.0 was used for data analysis, in which enumeration data were presented as percentage (%) with chi-square test for intergroup comparison, and measurement data were presented as mean ± standard deviation ( ) x s ± with t test for intergroup comparison. P < 0.05 suggested that the difference had statistical significance.
Results
Comparison of clinical efficacy of patients between the two groups
In the control group, there were 1 case with complete response (CR), 11 with partial response (PR), 7 with stable disease (SD), and 4 with progressive disease (PD); in the experiment group, there were 10 with CR, 8 with PR, 4 with SD, and 2 with PD. The total effectiveness rate in the experiment group was 75%, significantly higher than 52.18% in the control group (P < 0.05; Table 1 ).
Comparison of the levels of CEA and CA153 in serum between the two groups
Before treatment, there were no statistically significant differences in comparison of CEA and CA153 levels in serum between the two groups (P > 0.05), but when it came the 12th week after treatment, levels of CEA and CA153 in serum in the experiment group reduced more than those patients in control group (P < 0.05; Table 2 ).
Comparison of the adverse effects between the two groups
The incidence rate of adverse reaction in the experiment group was 29.2%, significantly lower than 47.8% in the control group (P < 0.05; Table 3 ).
Discussion
In clinical practice, there remains tremendous difficulties in diagnosis of NSCLC, and, due to the hidden symptoms, most patients have already progressed into the advanced stage at the time of diagnosis. Patients in the advanced stage can only receive chemotherapy, instead of the surgical resection for treatment. Conventional chemotherapeutic drugs, like cisplatin, though, can effectively alleviate the condition of lung cancer, as well has significant adverse reaction. 7 In recent years, molecular target therapy has become a hot spot and gradually applied in the treatment of lung cancer. Small-molecular epidermal growth factor receptortyrosine kinase inhibitor (EGFR-TKI) inhibitors, like gefitinib and erlotinib, can pass through the brain-blood barrier to kill the tumor cells. 8, 9 In this study, we developed the self-made sichongsan constituted by scorpio, centipede, earthworm, and stiff silkworm in the presence or absence of peach seed, Thunberg Fritillary Bulb, semen coicis, and asparagus fern, in which the worm drugs with effects of relief in dizziness, spasmolysis, detoxication, eliminating stagnation, dredging collaterals, and pain relief have shown promising efficacy on cancer pains. 10 Currently, few studies reported the clinical efficacy of self-made sichongsan in combination with gefitinib on the NSCLC patients with EGFR mutation. The results of this study showed that the objective response rate in the experiment group was 75%, significantly higher than 52.18% in the control group, while the incidence rate of the adverse effects in the experiment group was significantly lower than that in the control group.
CEA and CA153 as common tumor indicators are frequently used in the diagnosis and prognosis evaluation of cancers. 11, 12 The results of our study revealed that before treatment, there were no statistically significant differences in comparison of the levels of CEA and CA153 in serum between the two groups, but when it came to the 12th week after treatment, the levels in the experiment group deduced more than those in the control group, suggesting that self-made sichongsan in combination with gefitinib can significantly decrease the expressions of CEA and CA153 in serum of these patients, thereby facilitating the recovery.
In conclusion, in terms of the first-line treatment of NSCLC patients in advanced stage with EGFR mutation, self-made sichongsan in combination with gefitinib is superior to the simple administration of gefitinib in efficacy by reducing the levels of CEA and CA153 in serum and the incidence rate of adverse effects in a more efficient way. Thus, it is worthy of being promoted in clinical practice.
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